Stryker Recipe For Market Leading Growth Starts With Its Culture and Learnings

Key Points

• ChatGPT introduces "Work Mode," a new feature for taking action across apps and files, turning chaotic inputs into finished work, available on plus and pro plans.
• Optum uses data and technology to integrate patient care and pharmacy, aiming to make healthcare connected and simpler.
• Michigan markets itself as a business-friendly state with a resilient ecosystem, diverse talent, and quality of life, promoting growth for startups and enterprises.
• Bloomberg Intelligence hosts a discussion with Stryker’s CEO Kevin Lobo and COO Spencer Stiles about the company’s decentralized model, M&A strategy, and robotics innovation.
• Stryker’s success stems from its 22 business units, entrepreneurial culture, and a centralized integration team that improves acquisition outcomes.
• The Mako robotic acquisition was a risky but transformative bet, exceeding expectations and driving growth in orthopedics.
• Future robotics innovation combines hardware, software, and AI, with new platforms like Mako RPS targeting broader surgeon adoption.

Summary

The transcription covers three distinct promotional segments and a detailed interview. First, it advertises ChatGPT’s new "Work Mode," a feature designed to assist users in completing tasks by integrating across apps and files, transforming scattered information into polished outputs. It emphasizes efficiency for ambitious projects and is available on premium plans. Next, Optum highlights its mission to improve healthcare by leveraging data and technology to unify patient care, pharmacy services, and other aspects, making the system more connected and accessible. Finally, Michigan presents itself as an ideal location for business growth, citing its innovative ecosystem, diverse communities, and supportive environment for scaling companies.

The core content is an interview from the "Vanguards of Health Care" series, where Bloomberg Intelligence analyst Matt Henriksen speaks with Stryker’s CEO Kevin Lobo and COO Spencer Stiles. Stryker, a $25 billion medical device company, operates across orthopedics, neurovascular, and medical-surgical markets. Lobo, a nontraditional CEO with a finance background, joined Stryker 15 years ago, while Stiles has 27 years of experience, starting as a marketing associate and sales rep. They discuss Stryker’s decentralized operating model, comprising eight divisions and 22 business units, which fosters entrepreneurial leadership and executive retention.

A key focus is Stryker’s M&A strategy, with over 65 acquisitions under Lobo’s tenure. The company prioritizes "make vs. buy" decisions, using acquisitions as external R&D to fill capability gaps or accelerate time-to-market. They emphasize that integration is critical, with a centralized team driving post-close value creation. Early deals had mixed results, but repeated practice and a structured playbook improved success. Stryker builds relationships with targets over years, ensuring cultural fit, and integrates quickly—like putting the Stryker name on buildings within months—to create value.

The interview highlights the Mako robotic acquisition as a landmark deal. Lobo, with fresh perspective from outside orthopedics, saw robotics’ potential, noting Mako’s rapid market share gains in partial knees. Despite internal skepticism, the $1.6 billion bet paid off, exceeding expectations over 13 years. Looking ahead, robotics innovation combines hardware, implants, and software, with AI enhancing pre-planning and procedures like revisions. New products like Mako RPS, a handheld system, aim to attract surgeons hesitant about full robotic adoption, broadening the technology’s reach. Overall, the interview underscores Stryker’s culture, strategic discipline, and forward-thinking approach to medical technology.